Qualigen Therapeutics, Inc. has amended a secured promissory note with Marizyme, Inc. on August 21, 2025, increasing the principal balance to $4,451,462.18 due to prior loans and additional advances, with a repayment deadline of August 21, 2026. The company also reported shareholder equity exceeding $2.5 million as of June 30, 2025.